Is Your Diagnosis Correct? A Biopsy That Changed Everything
Is Your Diagnosis Correct? A Biopsy That Changed Everything
Of all the tests in medicine, a biopsy feels like the one that should settle things. Blood tests can fluctuate. Imaging can be ambiguous. Clinical examination depends on the physician doing it. But a biopsy — actual tissue from the body, examined under a microscope by a trained pathologist — seems like it should be beyond interpretation. Either the cells are cancerous or they aren't. Either the tissue shows disease or it doesn't.
That assumption, while understandable, is wrong. And for patients whose treatment decisions rest on a pathology report, it is an assumption worth examining carefully.
Pathology is a medical specialty, and like all medical specialties, it involves judgment — the trained interpretation of what is seen under a microscope. That interpretation can vary between pathologists. It can be influenced by the quality of the tissue sample, the preparation of the slides, the specific stains and techniques used, and the experience of the pathologist with the particular type of tissue being evaluated. In some cases, the difference between one pathologist's reading and another's is minor. In others, it is the difference between a cancer diagnosis and no cancer at all — or between two entirely different conditions requiring completely different treatment.
Two cases that came to Pilot Rock Medical Navigators put this in sharp relief. One involved a biopsy result that was incorrect, leading to a treatment path that changed entirely once the error was identified. The other involved a vasculitis diagnosis, made by a specialist, that was determined to be wrong — before an unnecessary biopsy was performed. Together, they illustrate something that every patient facing a significant biopsy result should understand: pathology is not infallible, and knowing that is the beginning of protecting yourself.
The Case of the Incorrect Biopsy
The patient had received a biopsy result that pointed clearly toward one diagnosis. Treatment was planned accordingly — a specific course of care based on what the pathology had reportedly shown. The clinical team moved forward with confidence in the result.
When the case reached Pilot Rock Medical Navigators for review, something gave pause. The diagnosis on the pathology report didn't fully align with the clinical picture — the symptoms, the history, the other findings — in a way that felt coherent. Dr. Sadock and his team identified the discrepancy and arranged for the pathology to be reviewed by an expert pathologist at a major academic medical center.
The review produced a different result. The original biopsy reading was incorrect. The actual diagnosis was something different — and the treatment appropriate for that diagnosis was meaningfully different from what had been planned. The patient's entire course of care changed based on what the second pathology review revealed.
This is not a story about a reckless original reading. Pathology errors of this kind occur even in good laboratories with skilled pathologists. What the case illustrates is that the margin for error in pathology is real, and that when the stakes are high — when a biopsy result is going to determine the course of treatment for a serious condition — verifying that result through an independent review is not excessive caution. It is appropriate care.
The Case Where an Incorrect Diagnosis Prevented an Unnecessary Biopsy
The second case is, in some ways, more dramatic. A patient had received a diagnosis of vasculitis — a serious inflammatory condition affecting blood vessels — from a specialist. A biopsy had been recommended to confirm the diagnosis.
Before the biopsy was performed, the case came to Pilot Rock for review. The review raised serious doubt about the vasculitis diagnosis. The clinical presentation, when examined carefully and in full context, was more consistent with a different condition — one that the biopsy wouldn't have confirmed, and that required a different diagnostic and treatment approach.
On the basis of that review, the biopsy was not performed. The patient was spared a procedure that carried real risk and would not have produced useful information, because the diagnosis prompting it was wrong.
This case illustrates the other side of the pathology coin: the value of questioning a diagnosis before an invasive test is performed, not only after. A biopsy is not a neutral procedure. Depending on location and technique, it can involve meaningful risk — bleeding, infection, nerve damage, or complications specific to the tissue being sampled. When the clinical reasoning leading to a biopsy recommendation is flawed, avoiding the procedure is itself a significant benefit.
How Pathology Errors Happen
Pathology is one of the most technical and specialized fields in medicine, and most pathologists are skilled, careful, and rigorous in their work. But the conditions under which pathology errors occur are real and worth understanding.
The quality of the tissue sample is the foundation of any pathological analysis. If the biopsy doesn't capture adequate tissue — if the needle missed the most representative area, or if the sample was too small to reveal the full picture — the pathologist is working with incomplete material. Some conditions are patchy or heterogeneous, meaning that what's present in one part of the tissue isn't present in another. A sample that misses the relevant area can produce a false negative or a misleading result.
Slide preparation matters significantly. The way tissue is processed, sectioned, and stained before it reaches the microscope affects what the pathologist sees. Different staining techniques reveal different features, and the choice of which techniques to apply is itself a judgment call that can influence the result. At major academic centers with specialized pathology departments, the range of techniques available and the experience with specific tissue types tends to be greater than at community hospitals.
Interobserver variability — the difference between how two qualified pathologists interpret the same slide — is a documented phenomenon across virtually every area of pathology. It is most pronounced in areas where the diagnostic criteria are subtle or contested: in distinguishing low-grade from high-grade tumors, in evaluating borderline lesions, in identifying rare conditions that require familiarity with a narrow spectrum of presentations. Research consistently finds that when pathology slides are sent to multiple pathologists for independent review, some degree of discordance in findings is common.
The pathologist's subspecialty expertise is another significant variable. Pathology, like clinical medicine, has become increasingly subspecialized. A pathologist with extensive experience in hematopathology — the study of blood and lymph tissue — brings a different depth of knowledge to a lymphoma diagnosis than a general pathologist who reviews all tissue types. For common conditions in common presentations, this difference may not be significant. For rare conditions, unusual presentations, or any case where the diagnosis is uncertain, it can be decisive.
What the Research Shows About Pathology Discordance
Studies examining the accuracy of pathology diagnoses across a range of tissue types and conditions have found discordance rates — differences between an original pathology reading and a second expert review — that are higher than most patients would expect.
In oncology, where the stakes of pathological accuracy are highest, the research is particularly instructive. Studies examining pathology second opinions at major cancer centers have found that clinically significant discordance — differences that change the diagnosis, the staging, or the treatment recommendation — occurs in roughly 10% to 20% of cases, depending on the cancer type and the study. For certain cancer types, including lymphomas, melanomas, and some soft tissue tumors, discordance rates in some studies are considerably higher.
A study published in the Journal of Clinical Oncology examining pathology second opinions at a major cancer center found that review of outside pathology specimens changed the diagnosis in a meaningful way in approximately one in seven cases. A separate analysis of breast cancer pathology found that second opinions altered the pathological diagnosis in roughly 8% of cases — a figure that translates to a significant number of patients affected when applied to the scale of breast cancer diagnoses nationwide.
These numbers don't mean that the original pathologist was negligent. They reflect the genuine complexity of pathological interpretation, the variation in subspecialty expertise across institutions, and the degree to which a second set of expert eyes — looking at the same tissue with the same rigor but a different knowledge base — can arrive at a different and sometimes more accurate conclusion.
Why Cancer Diagnoses Specifically Warrant Pathology Review
For patients who have received a cancer diagnosis, the argument for seeking an independent pathology review is particularly strong — for several reasons that compound each other.
First, the consequences of an incorrect cancer pathology are among the most serious in medicine. A cancer misidentified as a different type may be treated with chemotherapy or radiation that is effective for the diagnosed type but ineffective or harmful for the actual type. A cancer understaged may be undertreated. A benign condition misread as cancer may lead to surgery, radiation, or chemotherapy that a patient didn't need at all — with all the physical and psychological consequences those treatments carry.
Second, cancer pathology is among the most subspecialized areas of the field. There are pathologists who focus specifically on hematological malignancies, others who specialize in gastrointestinal cancers, others in soft tissue and bone tumors. The depth of expertise available at a major academic cancer center — with pathologists who have reviewed hundreds of cases of a specific cancer type — is meaningfully different from the expertise available at a community hospital where cancer cases represent a smaller fraction of the total pathology volume.
Third, treatment decisions in oncology are increasingly driven by molecular and genetic features of the tumor that require sophisticated analysis beyond standard microscopy. Immunohistochemistry, molecular profiling, next-generation sequencing — these are techniques that determine not just whether a cancer is present, but which specific subtype it is and which treatments are most likely to be effective. The availability and interpretation of these advanced analyses varies significantly between institutions.
For any patient who has received a cancer diagnosis and is preparing to begin treatment, having the pathology reviewed by a subspecialty pathologist at a major cancer center before treatment begins is a step that oncologists at major institutions take seriously — and one that every patient has the right to request.
How to Request a Pathology Second Opinion
The process for obtaining a pathology second opinion is more straightforward than most patients realize, and it does not require starting the diagnostic process over from the beginning.
Pathology second opinions are conducted by sending the actual slides — the glass slides containing the tissue sample — or digital scans of those slides to a pathologist at another institution for independent review. The original tissue block, from which additional slides can be cut if needed, remains at the originating institution.
The first step is contacting the pathology department at the institution where the original biopsy was performed and requesting that the slides be sent out for a second opinion review. Patients should specify where they want the slides sent — typically the pathology department of a major cancer center such as Memorial Sloan Kettering, Dana-Farber, MD Anderson, or Mayo Clinic. These institutions have robust pathology consultation services that are experienced in reviewing outside cases.
The request can be made directly by the patient, or a treating physician can make the request on the patient's behalf — and in many cases, a physician-initiated request moves more efficiently through the institutional process.
Patients should also obtain a copy of the original pathology report — the written document describing the pathologist's findings and conclusions. This report, along with the slides themselves, constitutes the primary material for the second opinion review.
Timelines for pathology second opinions vary by institution and by urgency. At major cancer centers, routine consultations may take one to two weeks; urgent cases, where treatment is time-sensitive, can often be expedited. The cost varies as well — some of this may be covered by insurance, particularly when the second opinion is considered medically necessary in the context of a cancer diagnosis, though patients should verify coverage in advance.
A medical navigator can facilitate this process significantly — identifying the most appropriate pathology department for the specific type of tissue and diagnosis involved, managing the logistics of slide transfer, and ensuring that the consulting pathologist receives the relevant clinical context alongside the physical material.
The Pathology Report Is a Starting Point, Not a Final Word
For patients who have received a biopsy result and are preparing to make significant treatment decisions based on it, the key takeaway from everything in this article is simple: the pathology report is the beginning of a diagnostic conclusion, not the definitive end of one.
This is especially true for cancer diagnoses, for rare conditions, for presentations where the clinical picture doesn't fully align with the pathology result, and for any case where the biopsy was performed at an institution without deep subspecialty expertise in the relevant tissue type.
Requesting a pathology second opinion is not an accusation of error. It is an acknowledgment that pathology, like all of medicine, involves interpretation — and that the stakes of getting it right are high enough to warrant verification. Most physicians who are confident in their pathological diagnosis will welcome an independent review, because a confirmed result gives everyone greater confidence and a corrected result prevents a patient from being treated for the wrong disease.
The two cases from Pilot Rock — one where a biopsy result was wrong and changed the entire treatment plan, one where a flawed diagnosis was caught before an unnecessary biopsy was performed — represent different points on the same spectrum. In both cases, the value of an independent clinical review was not hypothetical. It was immediate and concrete. And in both cases, the patient was better off for having had someone look carefully before moving forward.
____________
If you or a loved one has received a biopsy result that will guide a significant treatment decision, Pilot Rock Medical Navigators can help ensure that result has been properly verified. Book a free 15-minute introductory call to discuss your situation. Learn how Pilot Rock can help →